By Lauren Berg ( December 15, 2021, 9:43 PM EST) -- A Kansas federal judge on Wednesday largely denied Mylan's bid ahead of trial next month to decertify antitrust class action claims accusing the pharmaceutical company of causing a delay in the release of cheaper EpiPen generics, finding that the buyers have shown that most class members sustained an alleged injury....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.